FDA Approves Castration-Sensitive Prostate Cancer Drug
February 9th 2018Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release.
Read More
Combination Therapy That Includes Daratumumab Lowers Risk of Multiple Myeloma Progression
February 9th 2018Study results show patients with newly diagnosed multiple myeloma showed a lower risk of disease progression or death with daratumumab added to the standard regimen of bortezomib, melphalan and prednisone, than patients who were treated without daratumumab in their drug combination.
Read More